Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefazolin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.98 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 9/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefazolin SCHEMBL6364010 | 1.00 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL28254869 | 1.00 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL1698164 | 0.99 | LMNA (0.97) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2911037 | 0.99 | LMNA (0.97) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL11031717 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL16072809 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL4930576 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL3894722 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2842 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL3424683 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5950 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036754-A | Cefazolin sodium method for preparing anhydrous substance | 河北合佳创新医药科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2025111413-A1 | TREATMENT FOR SKIN DISORDERS | Mycotechnology, Inc. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-115015212-B | Spectral detection method for antiviral and antibacterial drug residues in water | 广东省科学院测试分析研究所(中国广州分析测试中心) | 2025-05-23 | — | — | CN | claimed |
| CN-119970732-A | Antibacterial composition with synergistic effect and application thereof | 南京工业大学 | 2025-05-13 | — | — | CN | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| CN-119780320-A | Method for measuring acetyl hydrazine in cefazolin sodium by high performance liquid chromatography-tandem mass spectrometry | 新发药业有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119757629-A | Method for detecting related substances in cefazolin sodium | 武汉九州钰民医药科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119733055-A | Composition of beta-lactam inhibitor and cephalosporin medicine, and preparation method and application thereof | 福建泽瑞药业有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119643765-A | Analysis method of cefazolin sodium and cefazolin sodium polymer impurities for injection | 上海上药新亚药业有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119510634-A | Polymer analysis method of cefazolin sodium for injection | 哈药集团技术中心 | 2025-02-25 | — | — | CN | claimed |
| EP-0327081-A2 | Alpha-crystals of cefazolin sodium | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-09 | — | — | EP | claimed |
| CN-87106855-A | The manufacture method of composition for oral liquid | — | 1988-04-20 | — | — | CN | claimed |
| CN-86105639-A | The preparation method of rectally dosage form | — | 1987-02-25 | — | — | CN | claimed |
| US-4486411-A | SYNERGISTIC MIXTURES WITH BETA-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1984-12-04 | — | — | US | claimed |
| US-4146971-A | Method of preparing a rapidly dissolving powder of sterile crystalline cefazolin sodium for parenteral administration | ELI LILLY AND COMPANY (US) | 1979-04-03 | — | — | US | claimed |
| US-4104391-A | Method of preparing stable sterile ampoules of crystalline cephalosporins for parenteral administration | ELI LILLY AND COMPANY (US) | 1978-08-01 | — | — | US | claimed |
| US-4104470-A | Crystallization process for cefazolin sodium | ELI LILLY AND COMPANY (US) | 1978-08-01 | — | — | US | claimed |
| US-4029655-A | Method of preparing stable sterile crystalline cephalosporins for parenteral administration | ELI LILLY AND COMPANY (US) | 1977-06-14 | — | — | US | claimed |
| US-4002748-A | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration | ELI LILLY AND COMPANY (US) | 1977-01-11 | — | — | US | claimed |
| US-3937655-A | Method for preparing stable β-lactam-type-antibiotic susceptibility test discs | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | claimed |